Skip to main content
SpringerLink
Log in

Myositis autoantibodies in Iranian myositis patients: assessment the frequency and clinical relevancy

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Introduction

Dermatomyositis (DM) and polymyositis (PM) are known as two major types of idiopathic inflammatory myopathies (IMMs). During the past years, growing data strongly suggest the clinical significance of myositis-associated autoantibodies (MAAs) and myositis-specific autoantibodies (MSAs). The present study aimed to determine the profile of MSAs and MAAs, subsequently to address the clinical significance of these autoantibodies in Iranian myositis patients.

Methodology

In this cross-sectional study, 28 DM and 24 PM patients were entered. Demographic and clinical characteristics were collected by direct examination and patients’ medical record. The existence of MSAs and MAAs was assessed by indirect immunofluorescence then using immunoblotting (FA 1510–1005-1, DL 1530–1601-4 G; Euroimmun, Germany). Data were analyzed using the SPSS software (v22; SPSS Inc. Chicago, IL, USA).

Results

The mean age of the patients was 46.18 ± 12.95 years and male/female ratio was 28.8/71.2. Autoantibodies were positive in 63.46% of myositis patients. Interestingly, anti-TIF1γ and anti-PL7 were significantly associated with malignancy (P < 0.001, P = 0.008; respectively). The existence of autoantibody and anti-Jo1 had significant relation with interstitial lung disease (ILD) (P = 0.034, P = 0.006; respectively). Joint involvements including arthritis and arthralgia were significantly associated with anti-Ro52 and anti-Jo1 (P = 0.04, P = 0.02; respectively).

Conclusion

Taken together, it can be concluded that certain myositis autoantibodies present clinical significance which is in line with the literature. The use of these autoantibodies as biomarkers by line blotting along with indirect immunofluorescence facilitates diagnosis of inflammatory myopathies and makes it more accurate as well as better management of myositis patients if used based on a science-based manner.

Key Points

• Identification of MSAs and MAAs facilitates the diagnosis of inflammatory myopathies and provides better myositis patient’s management if used according to a science-based manner.

• Anti-rod and ring antibody was detected in a patient with ovarian cancer–induced dermatomyositis.

• Malignancy and ILD are integrated parts of myositis which can be associated with MSAs and MAAs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Clark KE, Isenberg D (2018) A review of inflammatory idiopathic myopathy focusing on polymyositis. Eur J Neurol 25(1):13–23

    Article  CAS  Google Scholar 

  2. Schmidt J (2018) Current classification and management of inflammatory myopathies. J Neuromuscul Dis 5(2):109–129

    Article  Google Scholar 

  3. Dobloug C et al (2015) Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis 74(8):1551–1556

    Article  Google Scholar 

  4. McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nature Reviews. Rheumatology 14(5):290

    CAS  PubMed  Google Scholar 

  5. Riddell V, Bagby S, McHugh N (2020) Myositis autoantibodies: recent perspectives. Curr Opin Rheumatol 32(6):548–552

    Article  CAS  Google Scholar 

  6. Tieu J, Lundberg IE, Limaye V (2016) Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol 30(1):149–168

    Article  Google Scholar 

  7. Findlay AR, Goyal NA, Mozaffar T (2015) An overview of polymyositis and dermatomyositis. Muscle Nerve 51(5):638–656

    Article  CAS  Google Scholar 

  8. Hill CL et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96–100

    Article  CAS  Google Scholar 

  9. Moghadam-Kia S et al (2020) Risk factors and cancer screening in myositis. Rheum Dis Clin North Am 46(3):565–576

    Article  Google Scholar 

  10. Mimori T, Nakashima R, Hosono Y (2012) Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 14(3):264–274

    Article  CAS  Google Scholar 

  11. Gofrit SG et al (2018) The clinical phenotype of patients positive for antibodies to myositis and myositis-related disorders. Clin Rheumatol 37(5):1257–1263

    Article  CAS  Google Scholar 

  12. Allenbach Y et al (2016) Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol 186(3):691–700

    Article  CAS  Google Scholar 

  13. Uenaka T et al (2017) Less Limb Muscle Involvement in Myositis Patients with Anti-Mitochondrial Antibodies. Eur Neurol 78(5–6):290–295

    Article  CAS  Google Scholar 

  14. Yeker RM et al (2018) Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. Ann Rheum Dis 77(5):714–719

    Article  CAS  Google Scholar 

  15. Huang H-L et al (2020) The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease. Neurol Sci 42(7):2855–2864

  16. Betteridge Z et al (2019) Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 101:48–55

    Article  CAS  Google Scholar 

  17. Palterer B et al (2018) Bench to bedside review of myositis autoantibodies. Clin Mol Allergy 16(1):1–17

    Article  Google Scholar 

  18. Ceribelli A et al (2017) Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol 36(2):469–475

    Article  Google Scholar 

  19. Li L et al (2020) Analysis of myositis autoantibodies in Chinese patients with cancer-associated myositis. J Clin Lab Anal 34(8):e23307

    Article  CAS  Google Scholar 

  20. Yang H et al (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19(1):259

    Article  Google Scholar 

  21. Marie I et al (2012) Comparison of long-term outcome between anti-Jo1-and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11(10):739–745

    Article  CAS  Google Scholar 

  22. Vulsteke J-B et al (2019) Detection of myositis-specific antibodies. Ann Rheum Dis 78(1):e7

    Article  Google Scholar 

  23. Sabbagh S et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78(7):988

    Article  Google Scholar 

  24. Marie I et al (2012) Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 41(6):890–899

  25. Moll SA et al (2020) Prevalence of novel myositis autoantibodies in a large cohort of patients with interstitial lung disease. J Clin Med 9(9):2944

  26. Zhang L et al (2020) The value of anti-rods and rings antibodies in Western China population: a retrospective study. Scand J Immunol 91(3):e12848

    PubMed  Google Scholar 

  27. Shaikh Y, Krantz A, El-Farra Y (2013) Anti-rods and rings autoantibodies can occur in the hepatitis c-naïve population. J Prev Med Hyg 54(3):175

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Zhao L et al (2020) Myositis-specific autoantibodies in adults with idiopathic inflammatory myopathy: correlations with diagnosis and disease activity. Clin Rheumatol 40(3):1009–1016

  29. Mecoli CA et al (2020) Myositis autoantibodies: a comparison of results from the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot. Arthritis Rheumatol 72(1):192–194

    Article  Google Scholar 

Download references

Acknowledgements

We would like to express our special thanks of gratitude to the patients and their family as well as to the University of Shahed that helped us a lot in finalizing this project. Secondly, we would also like to thank deceased Dr. Soghrat Faghihzadeh who was the statistical supervisor of this project.

Author information

Authors and Affiliations

  1. Immunoregulation Research Center, University of Shahed, North kargar street, Tehran, Iran

    Milad Ebrahimi & Tooba Ghazanfari

  2. Department of Immunology, Faculty of Medicine, University of Shahed, Tehran, Iran

    Milad Ebrahimi & Tooba Ghazanfari

  3. Ward of Rheumatology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tohid Square, Tehran, Iran

    Abdolrahman Rostamian, Ramin Rafiei-Latianee, Seyed Reza Najafizadeh & Shafieh Movaseghi

  4. Ward of Rheumatology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

    Seyedeh Tahereh Faezi

Authors
  1. Milad Ebrahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdolrahman Rostamian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramin Rafiei-Latianee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seyed Reza Najafizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shafieh Movaseghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seyedeh Tahereh Faezi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tooba Ghazanfari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Abdolrahman Rostamian or Tooba Ghazanfari.

Ethics declarations

Disclosures

None

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ebrahimi, M., Rostamian, A., Rafiei-Latianee, R. et al. Myositis autoantibodies in Iranian myositis patients: assessment the frequency and clinical relevancy. Clin Rheumatol 41, 533–539 (2022). https://doi.org/10.1007/s10067-021-05879-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-021-05879-1

Keywords

Search

Navigation